Una alternativa esperanzadora “la terapia con esketamina intranasal en una paciente con depresión resistente”. A propósito de un caso

Galán-Armenteros, Rosa M; Romero-Mohedano, María C; González-González, Cristina; Marco-Feced, María A; Moreno-Campos, Antonio J.
Actas esp. psiquiatr ; 51(4): 184-187, Julio - Agosto 2023. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-226456

Documentos relacionados

  1. Safety of Intranasal Steroids: an Updated Perspective.
  2. Nanotechnologies for intranasal drug delivery: an update of literature.
  3. The Proposed Usage of Intranasal Steroids and Antihistamines for Otitis Media with Effusion.
  4. Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges.
  5. Paradoxical Effects of Intranasal Oxytocin on Trust in Inpatient and Community Adolescents.
  6. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program.
  7. Carbon Dioxide Changes during High-flow Nasal Oxygenation in Apneic Patients: A Single-center Randomized Controlled Noninferiority Trial.
  8. Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
  9. Quality by design (QbD) approach to formulate in situ gelling system for nose to brain delivery of Fluoxetine hydrochloride: Ex-vivo and In-vivo study
  10. Brain Metabolic Profile after Intranasal vs. Intraperitoneal Clomipramine Treatment in Rats with Ultrasound Model of Depression.